Tricuspid atresia medical therapy: Difference between revisions

	Tricuspid atresia Microchapters
Home
Patient Information
Overview
Pathophysiology
Causes
Differentiating Tricuspid Atresia from other Disorders
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography
Cardiac Catheterization
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Special Scenarios
Pregnancy
Case Studies
Case #1
Tricuspid atresia medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tricuspid atresia medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Tricuspid atresia medical therapy
CDC on Tricuspid atresia medical therapy
Tricuspid atresia medical therapy in the news
Blogs on Tricuspid atresia medical therapy
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Tricuspid atresia medical therapy

Revision as of 05:05, 2 October 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Keri Shafer, M.D. [2] Priyamvada Singh, MBBS [[3]]

Assistant Editor-In-Chief: Kristin Feeney, B.S. [[4]]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

“

Warfarin should be given for patients who have a documented atrial shunt, atrial thrombus, atrial arrhythmias, or a thromboembolic event. (Level of Evidence: C)

It is reasonable to treat systemic ventricle (SV) dysfunction with angiotensin-converting enzyme (ACE) inhibitors and diuretics. (Level of Evidence: C)

”

“

Management of patients with prior Fontan repair should be coordinated with a regional ACHD center. Local cardiologists, internists, and family care physicians should develop ongoing relationships with such a center with continuous availability of specialists. (Level of Evidence: C)
1. At least yearly follow-up is recommended for patients after Fontan repair. (Level of Evidence: C)
2. Arrhythmia management is frequently an issue, and consultation with an electrophysiologist is recommended as a vital part of care. (Level of Evidence: C)
3. New-onset atrial tachyarrhythmia should prompt a comprehensive noninvasive imaging evaluation to identify associated atrial/baffle thrombus, anatomic abnormalities of the Fontan pathway, or ventricular dysfunction. (Level of Evidence: C)

”

@@ Line 15: / Line 15: @@
 {{cquote|
 ===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]===
-# Warfarin should be given for patients who have a documented atrial shunt, atrial thrombus, atrial arrhythmias, or a thromboembolic event. (Level of Evidence: C)
+# [[Warfarin]] should be given for patients who have a documented atrial shunt, atrial thrombus, atrial arrhythmias, or a thromboembolic event. (Level of Evidence: C)
 ===[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]===
-# It is reasonable to treat systemic ventricle (SV) dysfunction with angiotensin-converting enzyme (ACE) inhibitors and diuretics. (Level of Evidence: C)}}
+# It is reasonable to treat systemic ventricle (SV) dysfunction with [[angiotensin-converting enzyme]] ([[ACE]]) inhibitors and diuretics. (Level of Evidence: C)}}
 ===ACC/AHA Guidelines - Recommendations for Management Strategies for the Patient with Prior Fontan Repair (DO NOT EDIT)===